The clinical utility of D-dimer/platelet count ratio in pregnant women. (17th September 2022)

• Record Type: Journal Article
• Authors: Limonta, G.; Intra, J.; Brambilla, P.
• Is Part Of: Journal of maternal-fetal & neonatal medicine. Volume 35:Number 18(2022)
• Page Start: 3602
• Page End: 3611
• Publication Date: 2022-09-17
• Subjects: Hypertension -- pregnancy -- D-dimer -- gestational hypertensive disorders -- Preeclampsia; Obstetrics -- Periodicals; Perinatology -- Periodicals; Infants (Newborn) -- Diseases -- Periodicals; Neonatology -- Periodicals; 618.2
• DOI: 10.1080/14767058.2020.1833322
• Languages: English
• ISSNs: 1476-7058

Abstract

Abstract: Objective: We performed a retrospective study to assess the clinical utility of a new index, D-dimer/platelet count (DD/PLT) ratio, in discriminating preeclampsia from normal pregnancy and gestational hypertension during third trimester, compared to the biomarkers currently used, such as D-dimer (DD), platelet (PLT), lymphocyte (LIN) and neutrophil (NEU) counts, fibrinogen (FIB), PLT/NEU, NEU/LIN and PLT/LIN ratios. Study design: We retrospectively included 213 subjects. Of them, 163 and 50 were singleton pregnant and healthy non-pregnant women, respectively. Among pregnant women, 105 had normal pregnancy, 33 had gestational hypertension, and 25 had preeclampsia. Results: Using Receiver Operating Curve (ROC) analysis, DD/PLT ratio showed significant higher area under the curve (AUC) (0.90; 95% confidence interval (CI) 0.84–0.95) in discriminating preeclampsia from normal pregnancy compared to those of DD, NEU, FIB, LIN, PLT/NEU, NEU/LIN and PLT/LIN ratios ( p < .03). In discriminating preeclampsia from gestational hypertension, the DD/PLT AUC (0.90; 95% CI 0.79–0.96) was significantly higher than those of DD, NEU, FIB, LIN, NEU/LIN and PLT/LIN ratios ( p < .03), and not statistically different from those of PLT ( p = .22) and PLT/NEU ratio ( p = .46). Conclusions: This study shows that DD/PLT ratio helps to discriminate preeclampsia from normal pregnancy and gestational hypertension. Large-scale studies are needed to verify its clinical usefulness, and to suggest more appropriate cutoff values for a widespread use.